JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Munir Boodhwani
Frank W. Sellke
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boodhwani, M.
Right arrow Articles by Sellke, F. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Boodhwani, M.
Right arrow Articles by Sellke, F. W.
Related Collections
Right arrow Cardiac - physiology
Right arrowRelated Article

J Thorac Cardiovasc Surg 2007;133:1686-1687
© 2007 The American Association for Thoracic Surgery

Letter to the Editor

Reply to the Editor

Munir Boodhwani, MD, MMSc, Frank W. Sellke, MD

Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass

The first 20% of the full text of this article appears below.

Statins are increasingly being used in patients with coronary disease. Recently, there has been increasing evidence from studies conducted in both in vitro and murine models that low-dose statins promote angiogenesis and high-dose statins inhibit it.1Go The application of these findings to patients is limited because of the lack of translation of the experimental models to the human setting. It is in this context that we examined the in vivo effects of high-dose atorvastatin in a clinically relevant large animal model of chronic myocardial ischemia and hypercholesterolemia. We found that atorvastatin treatment did not improve endogenous myocardial angiogenesis2Go or response to growth factor therapy,3Go despite improvement in endothelial function.

Czepluch and Waltenberger make the important point that the dose of statins used may be too high for clinical relevance and indeed may be toxic. The first thing to note is that, for initial toxicity studies, as much as 80 . . . [Full Text of this Article]


Related Article

High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine: Relevance to the human situation?
Frauke S. Czepluch and Johannes Waltenberger
J. Thorac. Cardiovasc. Surg. 2007 133: 1685-1686. [Extract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.